Gritstone bio, Inc.
NASDAQ:GRTS
0.55 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Gritstone bio, Inc. |
Symbool | GRTS |
Munteenheid | USD |
Prijs | 0.551 |
Beurswaarde | 65,030,815 |
Dividendpercentage | 0% |
52-weken bereik | 0.42 - 3.33 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. |
Website | https://gritstonebio.com |
An error occurred while fetching data.
Over Gritstone bio, Inc.
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)